logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

New Stock News | Luckin Technology's Hong Kong IPO prospectus has expired.

date
06/08/2026
According to the Zhito Finance APP, Luckin Technology (Beijing) Co., Ltd. (abbreviated as: Luckin Technology) submitted its Hong Kong stock prospectus on February 6, 2026, which will expire on August 6, 2026, after being valid for 6 months. China Galaxy International was its sole sponsor at the time of submission.
Latest
2 m ago
Renesas Electronics will showcase embodied intelligent robotic solutions.
3 m ago
Shengjian Technology has established a new subsidiary with a registered capital of 30 million yuan.
3 m ago
China responds to the U.S. blocking normal cooperation between Chinese and Arab enterprises.
3 m ago
Hong Kong Stock Movement | Contemporary Amperex Technology Co., Ltd. (03750.HK) falls over 3% as institutions indicate that the company's gross profit for the second quarter was below expectations, triggering a new round of market concerns.
4 m ago
Hong Kong Stock Movement | Kelun-Botai Biotech (06990.HK) rose over 4% in the morning as the clinical trial application for the new dual-delivery ADC drug SKB565 was approved.
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.